Sign in Register

Drug class

Inhaled Aminoglycosides

Inhaled aminoglycosides are a targeted route-specific subcategory of aminoglycoside antibacterial drugs formulated for aerosol or dry-powder administration directly into the respiratory tract. Read more about Inhaled Aminoglycosides

23 drugs in this class 18 manufacturers

Related classes & indications

Antimalarial DrugsAnti-infectives · 223 prescription drugs Antiprotozoal AgentsAnti-infectives · 102 prescription drugs

Showing 19–23 of 23 drugs

Sort

TOBRAMYCIN (tobramycin in 0.225 % sodium chloride)

INHALED AMINOGLYCOSIDES · SYNERGY FOR P. AERUGINOSA INFECTION IN CYSTIC FIBROSIS ·+1

ASCEND LABORATO

TOBRAMYCIN (tobramycin in 0.225 % sodium chloride)

INHALED AMINOGLYCOSIDES · SYNERGY FOR P. AERUGINOSA INFECTION IN CYSTIC FIBROSIS ·+1

LIFESTAR PHARMA

TOBI (tobramycin in 0.225 % sodium chloride)

INHALED AMINOGLYCOSIDES · SYNERGY FOR P. AERUGINOSA INFECTION IN CYSTIC FIBROSIS ·+1

Viatris Specialty

TOBI PODHALER (tobramycin)

INHALED AMINOGLYCOSIDES · SYNERGY FOR P. AERUGINOSA INFECTION IN CYSTIC FIBROSIS ·+1

Viatris Specialty

TOBRAMYCIN (tobramycin in 0.225 % sodium chloride)

INHALED AMINOGLYCOSIDES · SYNERGY FOR P. AERUGINOSA INFECTION IN CYSTIC FIBROSIS ·+1

RITEDOSE PHARMA

Filter & compare in the drug finder → Opens the drug finder with Inhaled Aminoglycosides preselected. Add indication or manufacturer filters there.

About Inhaled Aminoglycosides.

Inhaled aminoglycosides are a targeted route-specific subcategory of aminoglycoside antibacterial drugs formulated for aerosol or dry-powder administration directly into the respiratory tract.

They exert bactericidal activity by binding to the bacterial 30S ribosomal subunit to disrupt protein synthesis, delivering high local drug concentrations directly to the endobronchial space while limiting systemic absorption and associated nephrotoxicity and ototoxicity.

Agents in this class—most notably inhaled tobramycin and inhaled liposomal amikacin—are primarily indicated for the management of chronic pulmonary infections, including *Pseudomonas aeruginosa* airway colonization in cystic fibrosis and refractory *Mycobacterium avium* complex lung disease.

fda.gov
Inhaled aminoglycosides are a targeted route-specific subcategory of aminoglycoside antibacterial drugs formulated for aerosol or dry-powder administration directly into the respiratory tract Agents in this class—most notably inhaled tobramycin and inhaled liposomal amikacin—are primarily indicated for the management of chronic pulmonary infections, including *Pseudomonas aeruginosa* airway colonization in cystic fibrosis and refractory *Mycobacterium avium* complex lung disease
fda.gov
Inhaled aminoglycosides are a targeted route-specific subcategory of aminoglycoside antibacterial drugs formulated for aerosol or dry-powder administration directly into the respiratory tract They exert bactericidal activity by binding to the bacterial 30S ribosomal subunit to disrupt protein synthesis, delivering high local drug concentrations directly to the endobronchial space while limiting systemic absorption and associated nephrotoxicity and ototoxicity
fda.gov
Inhaled aminoglycosides are a targeted route-specific subcategory of aminoglycoside antibacterial drugs formulated for aerosol or dry-powder administration directly into the respiratory tract They exert bactericidal activity by binding to the bacterial 30S ribosomal subunit to disrupt protein synthesis, delivering high local drug concentrations directly to the endobronchial space while limiting systemic absorption and associated nephrotoxicity and ototoxicity Agents in this class—most notably in...
nih.gov
They exert bactericidal activity by binding to the bacterial 30S ribosomal subunit to disrupt protein synthesis, delivering high local drug concentrations directly to the endobronchial space while limiting systemic absorption and associated nephrotoxicity and ototoxicity
nih.gov
They exert bactericidal activity by binding to the bacterial 30S ribosomal subunit to disrupt protein synthesis, delivering high local drug concentrations directly to the endobronchial space while limiting systemic absorption and associated nephrotoxicity and ototoxicity
fda.gov
Agents in this class—most notably inhaled tobramycin and inhaled liposomal amikacin—are primarily indicated for the management of chronic pulmonary infections, including *Pseudomonas aeruginosa* airway colonization in cystic fibrosis and refractory *Mycobacterium avium* complex lung disease